Western Regional Medical Center
23
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
91.3%
21 terminated/withdrawn out of 23 trials
4.5%
-82.0% vs industry average
0%
0 trials in Phase 3/4
1300%
13 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Role: lead
Quality of Life Assessment of Cryotherapy in Esophageal or Gastroesophageal Cancer
Role: lead
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Role: lead
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Role: lead
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Role: lead
Fasting on Newly Diagnosed Breast Cancer
Role: lead
Interleukin-2 in Metastatic Melanoma
Role: lead
Dacarbazine and Carmustine in Metastatic Melanoma
Role: lead
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Role: lead
Capecitabine With Digoxin for Metastatic Breast Cancer
Role: lead
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Role: lead
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Role: lead
Interleukin-2 in Metastatic Kidney Cancer
Role: lead
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Role: lead
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
Role: lead
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer
Role: lead
Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment
Role: lead
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
Role: lead
Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
Role: lead
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Role: lead